Listen and subscribe to Morningstar’s The Long View from your mobile device: Apple Podcasts | Spotify Hi, and welcome to The ...

I've been working on a dissertation for an amount of time that will remain undisclosed, and I'm either writing or avoiding writing by reading. I read a lot of books and PDFs ... I have been testing ...

She kept four journals, one each for her husband and her three grown children, and mustered the strength to write her thoughts ... and treatment to a person’s unique biochemical makeup.

injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced Parkinson disease, according to a news release from ...

Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Feb. 6. 2025 – The FDA has approved a new wearable device for adults with advanced Parkinson’s disease. Sold as Onapgo, this device gives a steady dose of apomorphine – a medicine that ...

A new Supernus Pharmaceuticals medical device that continuously administers an old Parkinson’s disease drug is now FDA approved, giving patients another way to manage the motor control symptoms ...

Feb 4 (Reuters) - The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' (SUPN.O), opens new tab drug-device combination to treat movement-related symptoms of Parkinson's ...

Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease ... up 5.5% to $39.42. Write to Colin Kellaher at colin ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease. The US FDA this week approved the sale of the treatment, which ...